瑞普生物：生物制品板块下半年重点推出新支二联活疫苗等大单品

Core Viewpoint - The company, Reap Bio, announced the launch of several new products in its biopharmaceutical, drug formulation, and pet care segments for the second half of the year, focusing on advanced vaccine technology and innovative treatments for various animal health needs [1] Group 1: Biopharmaceutical Segment - The company plans to introduce new vaccines, including the new dual live vaccine and new inactivated vaccines targeting key poultry diseases, enhancing multi-valent technology and broad-spectrum antigens [1] - The upgrades aim to meet diverse vaccination needs across different farming scenarios, indicating a strategic focus on addressing core disease challenges in poultry farming [1] Group 2: Drug Formulation Segment - The company will launch its independently developed long-acting sustained-release formulation of Cefoperazone crystals and its injectable form [1] - Additionally, it will introduce a new crystal form of Vornidazole hydrochloride with independent intellectual property rights, targeting Mycoplasma infections in poultry for the first time [1] Group 3: Pet Care Segment - The company aims to enhance its product matrix in the pet care sector by launching new products such as cat interferon, krill oil, and probiotics [1] - This initiative is part of a broader strategy to provide a comprehensive range of products from prevention to treatment and nutritional health, showcasing the continued emphasis on product cluster scale effects [1]